Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
0.9300
Dollar change
-0.0700
Percentage change
-7.00
%
Index- P/E- EPS (ttm)-1.49 Insider Own7.52% Shs Outstand39.54M Perf Week-2.60%
Market Cap36.77M Forward P/E- EPS next Y-1.80 Insider Trans0.00% Shs Float36.57M Perf Month-30.60%
Income-58.07M PEG- EPS next Q-0.46 Inst Own17.08% Short Float0.03% Perf Quarter-27.34%
Sales15.12M P/S2.43 EPS this Y17.98% Inst Trans4.32% Short Ratio0.23 Perf Half Y-50.92%
Book/sh4.02 P/B0.23 EPS next Y-14.66% ROA-27.74% Short Interest0.01M Perf Year-69.45%
Cash/sh2.68 P/C0.35 EPS next 5Y- ROE-32.74% 52W Range0.81 - 4.16 Perf YTD-74.80%
Dividend Est.- P/FCF- EPS past 5Y- ROI-34.16% 52W High-77.64% Beta-0.72
Dividend TTM- Quick Ratio8.93 Sales past 5Y4086.64% Gross Margin61.41% 52W Low14.81% ATR (14)0.12
Dividend Ex-Date- Current Ratio8.93 EPS Y/Y TTM26.58% Oper. Margin-427.02% RSI (14)38.53 Volatility10.86% 13.55%
Employees130 Debt/Eq0.08 Sales Y/Y TTM106.80% Profit Margin-384.00% Recom1.00 Target Price7.25
Option/ShortNo / Yes LT Debt/Eq0.07 EPS Q/Q42.72% Payout- Rel Volume0.82 Prev Close1.00
Sales Surprise- EPS Surprise52.63% Sales Q/Q- EarningsNov 06 BMO Avg Volume50.49K Price0.93
SMA20-14.25% SMA50-23.52% SMA200-47.35% Trades Volume41,500 Change-7.00%
Date Action Analyst Rating Change Price Target Change
May-25-21Initiated William Blair Outperform
May-25-21Initiated Morgan Stanley Overweight $22
May-25-21Initiated Jefferies Buy $28
May-24-21Initiated H.C. Wainwright Buy $25
Nov-25-24 04:01PM
Nov-15-24 11:02AM
11:01AM
Nov-06-24 08:00AM
Oct-31-24 08:00AM
08:00AM Loading…
Oct-01-24 08:00AM
Sep-24-24 08:00AM
Aug-08-24 08:00AM
Aug-01-24 08:00AM
Jun-12-24 04:01PM
Jun-06-24 11:15AM
May-22-24 08:00AM
May-13-24 01:53PM
08:00AM
May-01-24 07:00AM
04:10PM Loading…
Apr-18-24 04:10PM
Mar-20-24 01:52PM
08:15AM
Jan-05-24 04:01PM
Dec-21-23 07:31AM
Nov-09-23 04:24PM
04:01PM
04:01PM
Nov-06-23 09:05AM
Oct-04-23 06:23AM
Sep-13-23 08:00AM
Aug-10-23 08:00AM
Aug-09-23 07:37AM
Jul-19-23 08:34PM
Jun-29-23 07:11AM
06:49AM Loading…
06:49AM
Jun-21-23 09:03AM
07:30AM
Jun-12-23 07:30AM
May-19-23 06:04AM
May-12-23 08:00AM
May-05-23 07:33AM
Apr-17-23 09:00AM
Apr-05-23 01:40PM
Mar-28-23 08:00AM
Mar-24-23 08:06AM
Mar-20-23 12:44PM
08:00AM
Mar-16-23 06:47AM
Mar-01-23 06:01AM
Jan-30-23 08:00AM
Jan-13-23 05:24AM
Nov-21-22 10:31AM
Nov-13-22 07:29AM
Nov-10-22 04:30PM
Nov-09-22 08:00AM
Nov-07-22 08:00AM
Nov-02-22 08:00AM
Oct-31-22 08:00AM
Oct-27-22 07:00AM
Oct-06-22 11:45AM
Oct-03-22 04:30PM
Sep-20-22 04:30PM
Sep-07-22 04:01PM
12:00PM
Aug-15-22 06:14AM
Aug-11-22 09:14AM
Aug-09-22 04:15PM
Jul-07-22 04:15PM
Jul-03-22 10:08AM
Jun-22-22 01:34PM
06:00AM
Jun-06-22 04:15PM
07:32AM
May-20-22 11:30AM
May-19-22 06:32AM
May-11-22 04:15PM
Apr-29-22 10:30AM
Apr-06-22 04:15PM
Mar-25-22 07:15AM
Mar-07-22 08:00AM
Jan-21-22 03:41AM
Jan-18-22 03:00AM
Jan-13-22 04:34PM
Jan-10-22 10:00AM
Dec-13-21 04:05PM
Dec-07-21 08:00AM
Nov-24-21 09:20AM
Nov-12-21 08:00AM
07:00AM
Nov-10-21 08:00AM
Nov-04-21 04:00AM
Oct-28-21 01:23PM
Oct-18-21 08:00AM
Oct-13-21 08:00AM
Sep-13-21 12:38PM
Sep-09-21 08:00AM
Aug-12-21 08:00AM
Jul-30-21 10:00AM
Jul-08-21 08:00AM
Jul-06-21 10:19AM
07:00AM
Jun-20-21 08:00PM
Jun-14-21 05:49PM
Jun-01-21 08:00AM
Barinthus Biotherapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer. It also focuses on the pipeline of both clinical and preclinical stage therapeutic, and prophylactic programs. The company was founded by Adrian Hill and Dame Sarah Gilbert in March 2021 and is headquartered in Didcot, the United Kingdom.